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Abstract. Background/Aim: We investigated the effects of
luteolin (LUT) on classical Hodgkin’s lymphoma (cHL), since
such studies in malignant lymphomas are lacking. Materials
and Methods: Effect of LUT on cell growth was assessed with
water-soluble tetrazolium 1 (WST-1) cell proliferation assay
and automated hemocytometry on trypan blue-exclusion assay.
Cell death was investigated with acridine orange/ethidium
bromide live-dead assay, propidium iodide (PI) flow
cytometry, and Annexin-V-PI microscopy. Caspase activation
was studied using CellEvent Caspase-3/7 Green detection
reagent. High resolution immunofluorescence microscopy was
used to detect cleaved-PARP-1. Results: LUT induced a dose-
dependent decrease in the growth of KMH2 and L428 cells,
cellular models of mix-cellularity (MC) and nodular sclerosis
(NS) cHL, respectively. However, LUT induced cell death only
in KMH2, at a higher concentration, and this was associated
with caspase activation and cleaved PARP-1. Conclusion:
LUT induces cytotoxicity in the MC-cHL cellular model
KMH2 via caspase activation. 
While current frontline treatment regimens, which include
ABVD (adriamycin, bleomycin, vinblastine, and dacarbazine)
result in a high cure rate in classical Hodgkin’s lymphoma
(cHL) (1), disease relapse, refractory disease, treatment-related
toxicities, and development of secondary neoplasms, remain
significant concerns (2). In addition, only less than 50%
patients who fail frontline therapy and subsequently treated
with either autologous stem cell transplant (ASCT) or
Brentuximab vedotin show clinical responses (3, 4). To
mitigate these concerns associated with poor clinical responses
in cHL, one line of research is focused on the development
and discovery of new therapeutic approaches. 
Luteolin (3,4,5,7-tetrahydroxy flavone, LUT), a flavonoid
found in common foods, has been widely studied for its anti-
cancer potential, as demonstrated in studies in multiple
human malignancies such as lung, breast, glioblastoma,
prostate, colon, and pancreatic cancers (5). LUT has been
shown to trigger apoptosis (6, 7), inhibit cell growth,
stimulate cell cycle arrest (6, 7) and disrupt metastasis (8)
and cell migration (8, 9). However, although increased
dietary intake of flavonoids was associated with reduced risk
of disease occurrence in non-Hodgkin’s lymphoma, (10),
there is very limited information about the effects of LUT on
hematological malignancies. In myeloid leukemia, LUT-
induced apoptosis is modulated by the differential expression
of the oncoprotein PTTG1 (pituitary tumor-transforming
gene 1) (11). In multiple myeloma, LUT causes cell death by
apoptosis and autophagy (12). To date however, there is no
study on the effect of LUT on malignant lymphomas.
Therefore, the goal of this current study was to investigate
the potential anti-cancer effects of LUT on cHL.
Materials and Methods
Drug. LUT was purchased from SelleckChem (Houston, TX, USA)
and dissolved in DMSO (Sigma-Aldrich, St. Louis, MO, USA) to
prepare a 50-mM stock, which was aliquoted and stored at −20˚C
until ready to be used. All working stocks of LUT were prepared to
a final concentration of 0.01% DMSO. 
Cell lines and cell cultures. The human HRS-derived cell lines
KMH2 and L428 were obtained from the German Collection of
Microorganisms and Cell Cultures (DSMZ), Department of Human
and Animal Cell Cultures, Braunschweig, Germany. L428 and
KMH2 were cultured in RPMI 1640 medium supplemented with
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10% heat-inactivated fetal bovine serum (FBS) (Gibco,
Gaithersburg, MD, USA), 1% L-glutamine (Thermo Fisher
Scientific, Waltham, MA, USA) and penicillin/streptomycin
(Thermo Fisher Scientific). Cells used in these experiments were
from an early passage (L428 and KMH2 passage 3), and tested
negative for mycoplasma infection (13, 14). All cells were
maintained in a humid environment of 5% CO2 at 37˚C.
WST-1 cell proliferation assay. Cell growth was assessed with WST-1
cell proliferation assay (Roche; Branchburg, NJ, USA), according to
manufacturer’s instructions and as described by Gharbaran et al. (15).
One hundred μl of 1×105 cells/ml were seeded in a 96-well plate, and
incubated overnight. Cells were then treated with 0, 20, 40, and 80 μM
of LUT or DMSO for 48 h. The treated cells were incubated with 10
μl WST-1 reagent for 3 h following standard cell culture conditions.
Absorbance was read at 450 nm on a Synergy H1 Hybrid microplate
reader (BioTek Instruments; Winooski, VT, USA). Cell growth (in
percentages, %) was computed as a ratio of the absorbance (A450) of
LUT-treated cells to the absorbance of the DMSO control. The assay
principle is based on the conversion of the tetrazolium salt WST-1 into
a colored dye by mitochondrial dehydrogenase enzymes.
Trypan blue exclusion assay and hemocytometry. LUT-induced
changes in cell viability and cell growth were determined by trypan
blue exclusion assay and hemocytometry using an EVE automated
cell counter (NanoEnTek; Guro-gu, Seoul, Korea), according to the
manufacturer’s instructions. One hundred μl of 1×105 cells/ml
seeded in 96-well plates were treated with 0, 20, 40 and 80 μM
LUT or DMSO, for 48 h. Ten μl of a suspension of treated cells
were mixed with 10 μl 0.4% trypan blue. Ten μl of this mixture
were then loaded into a counting chamber. 
Acridine orange and ethidium bromide live/dead assay. Acridine
orange (AO)-ethidium bromide (EtBr)—AO/EtBr-- assay was used
to determine cell death. One hundred μl of 1×105 cells/ml were
seeded in 96-well plates overnight and then treated with 40 μM
LUT or vehicle, for 48 h. Four μl of a solution consisting of 10
μg/ml each of AO and EtBr were added to each well of treated cells
and immediately imaged. In this assay, the membrane-permeable
AO stained live cells green and EtBr, which is membrane-
impermeable, stained the nuclei of dead cells orange to red.
Annexin V FITC- propidium iodide assay. Annexin V-propidium
iodide staining was carried out using Annexin V FITC Assay Kit
(Cayman Chemicals; Ann Arbor, MI, USA), according to the
manufacturer’s instructions. One hundred μl of 1×105 cells/ml were
seeded in 96-well plates overnight and treated with 40 μM LUT or
vehicle, for 48 h. Treated cells were transferred to a microfuge tube
and collected by centrifugation at 400 × g for five min at room
temperature, and then resuspended in 100 μl 1 X binding buffer.
Cells were then centrifuged as described and incubated in 50 μl
Annexin V FITC/Propidium Iodide Staining Solution for 10 min at
room temperature in a dark chamber. Stained cells were collected
by centrifugation and resuspended in binding buffer. Cells were then
transferred to chamber slides containing poly D-lysine for
microscopy analysis.
Flow cytometry analysis and detection of sub-G1 cell population.
Cells were seeded into 6-well plates at 1×105 cells/well, incubated
overnight, and then treated with 40 μM LUT for 48 h. Harvested
cells were fixed in 70% ethanol, collected by centrifugation, and
re-suspended in PBS containing 10 μg/ml Propidium Iodide (PI)
and 300 μg/ml RNAse A (Cell Signaling; Danvers, MA, USA) for
15 min at room temperature. The stained cells were analyzed on
a BD LSRII flow cytometer and collected data were analyzed by
FlowJo software (version 10; Tree Star, Ashland, OR, USA). In
this assay, fragmented DNA was not retained following ethanol
fixation and such cells were detected as the sub-G1 population
(apoptotic cells). 
Detection of caspase activities. Caspase3/7 activities were analyzed
using the CellEvent Caspase-3/7 Green Detection Reagent (Life
Technologies, CA, USA), according to manufacturer’s instructions.
Cells seeded into 96-well plates at a density of 1×105 cells/ml were
incubated overnight, and then treated with 40 μM LUT or DMSO
for 48 h. Cells were then incubated with CellEvent Caspase-3/7
Green Detection Reagent to a final concentration of 2 μM for 30
min, following standard cell culture conditions. These experiments
included LUT-treated cells pre-incubated for 1 h with the pan-
caspase inhibitor Z-VAD-FMK (BioVision; Milpitas, CA, USA).
Microscopy. Microscopy was carried out as previously described
(15). Images for live/dead assay, casp3/7 activation, and annexin V-
FITC/PI analyses, were generated from randomly selected fields.
About 5 to 10 fields were imaged per dose. Cell counts on images
were carried out manually, blindly, by independent counters (counts
were carried out by researchers who did not know what sample the
images represent). 
Cellular immunofluorescence. Immunofluorescence was carried out
according to Gharbaran et al. (15) with some modifications. Cells
adhered to poly-D lysine (Sigma-Aldrich) coated number 1
coverslips for 30 min in a humid chamber at 37˚C in 5% CO2,
rinsed 1 × with PBS, and then fixed for 20 min with 3.7%
paraformaldehyde (Electron Microscopy Sciences 15710, Hatfield,
PA, USA). Fixed cells were permeabilized with 0.1% PBS-Triton
X-100 (Sigma–Aldrich) for 30 min, then blocked for 30 min in 1%
normal goat serum followed by incubation with anti-cleaved PARP-
1 rabbit monoclonal antibody (clone Y34, Abcam; Cambridge, MA,
USA) diluted 1:200 in blocking buffer for 1 h, followed by three
rinses for 5 min each with 0.1% PBS-Tween 20. The cells were next
incubated with Dylight-488 labeled secondary antibody (Jackson
ImunoResearch; West Grove, PA, USA) diluted at 1:500 in blocking
buffer, from a stock prepared in 50% glycerol. Stained cells were
mounted in ProLong Gold anti-fade reagent containing DAPI (Life
Technologies, Carlsbad CA, USA) and images were captured with
a CoolSNAP HQ2 CCD camera (Cool SNAP EZ, Photometrics,
Tucson, AZ, USA) coupled to a Nikon Ti Eclipse inverted
microscope (Melville, NY, USA). 
Statistical analyses. Data analyses were performed using SAS
9.1.3 (Cary, NC, USA) and StatView 5 (Cary, NC, USA).
Analysis of variance (ANOVA) and F statistics were used to
determine significant differences between the means as defined
by p<0.05. Data obtained from the assays on cell growth, cell
viability, AO/EtBr, Annexin V-PI, caspase3/7, and flow
cytometry, are presented as plus or minus standard error of the
mean (±SEM). For the cell growth assay, the mean per dose was
determined from triplicates. Each experiment was repeated at
least three times.
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Results
Effect of LUT on cell growth. WST-1 cell proliferation assay
and automated hemocytometry on trypan blue exclusion
assay were used to independently evaluate the effects of
LUT on cell growth, following treatment for 48 h. LUT
significantly inhibited the growth of both KMH2
(p<0.00001) and L428 (p<0.00001) cells in a dose-
dependent manner (Figure 1A). Automated hemocytometry
after trypan blue exclusion assay revealed a similar trend
(Figure 1B). However, although both cell lines showed
comparable changes in cell growth at higher doses of LUT,
the automated hemocytometry detected a lower proportion
of KMH2 viable cells (52%) compared to L428 (92%)
(Figure 1C). Microscopic examination of treated cells with
higher doses of LUT revealed a larger proportion of KMH2
cells with compromised membranes compared to L428 cells
(data not shown). These results indicated that LUT, at higher
doses, may be strongly inducing death of KMH2 cells, a
cellular model of MC-cHL.
LUT induces apoptosis in KMH2. LUT-treated KMH2 cells
were next studied for cell death. AO/EtBr live-dead staining of
KMH2 cells treated with 40 μM LUT for 48 h showed
increased cell death. As shown in Figure 2A, the mean percent
of EtBr-positive cells (stained red) was 33.6% (±2.08%)
compared to DMSO control (7.27%±1.09%) (p<0.00001).
LUT-induced cell death was further investigated with Annexin
V-PI microscopy. As shown in Figure 2B, Annexin V-PI
positive cells were significantly higher in LUT-treated KMH2
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Figure 1. Effect of luteolin (LUT) on the growth of KMH2 and L428 cells. A. WST-1 analyses of LUT induced dose-dependent decrease in the growth
of KMH2 and L428 cells. B. Automated hemocytometry data on LUT-induced dose-dependent decrease in cell growth. C. Automated hemocytometry
on trypan blue-stained cells revealed a significantly lower proportion of viable KMH2 cells compared to L428, after treatment with 40 μM of LUT.
Cells were treated with 0, 20, 40, and 80 μM of LUT for 48 h. Cell growth was evaluated independently with WST-1 cell proliferation assay and
trypan blue exclusion assay. Significantly different at *p<0.05 and **p<0.01 as compared to the control group. Results are presented as the
mean±standard error.
(38.9%±1.92) compared to DMSO-treated cells (6.55%±0.94%)
(p<0.00001). Additionally, flow cytometry analysis of ethanol-
fixed PI-stained cells showed a statistically significantly higher
percentage of LUT-treated KMH2 cells in the sub-G1 phase
(28.6%±2.00%) compared to DMSO-treated cells (7.16%±0.43)
(p<0.00001) (Figure 2C). 
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Figure 3. Effect of LUT on caspase and PARP-1 activities in KMH2 cells. A. LUT treatment resulted in a significantly higher number of caspase3/7-
positive cells. B. Cleaved PARP-1 (green fluorescent) was detected in LUT-treated cells, but was absent in DMSO-treated control cells. Cells were
treated with 40 μM of LUT or DMSO for 48 h and analyzed using CellEvent Caspase-3/7 Green Detection Reagent and anti-cleaved PARP-1
immunofluorescence microscopy. Significantly different at **p<0.01 compared to the control group. Results are presented as the mean±standard
error. Scale bar in A is 100 μm, and that for B is 10 μm.
Figure 2. Effect of LUT on death of KMH2 cells. A. Acridine orange/ethidium bromide (AO/EtBr) staining detected significantly higher number of
dead cells (red) due to LUT treatment compare to DMSO. B. Significantly higher proportion of Annexin V/PI-positive cells were detected after LUT
treatment compared to DMSO. C. Flow cytometry-PI detected higher levels of apoptosis after LUT treatment compared to DMSO. Cells were treated
with 40 μM of LUT or DMSO for 48 h. Significantly different at *p<0.05 and **p<0.01 as compared to the control group. Results are presented as
the mean±standard error.
Activation of caspase activities in KMH2 and detection of
cleaved PARP-1. To gain insights into the putative
mechanism of LUT-induced cell death, LUT-treated KMH2
cells were assessed for caspase activities. A caspase3/7-
specific fluorochrome detection dye revealed significantly
higher levels of caspase3/7-postive cells (stained green) in
the LUT-treated KMH2 cells (30.7%±3.7%) compared to
either DMSO (4.77%±0.63%) or LUT-treated cells pre-
incubated with the pan-caspase inhibitor Z-VAD-FMK
(5.34%±0.58%) (p<0.00001) (Figure 3A). Since KMH2 cells
are caspase 3-deficient (16), it is likely that LUT triggered
activation of caspase7 in this cell line. 
PARP-1, a DNA-repair enzyme, is a cellular substrate for
caspases (17) and both PARP-1 cleavage and caspase7
activation have been observed in KMH2 cells treated with
doxorubicin and camptothecin (18). LUT-treated KMH2 cells
were therefore studied for PARP-1 activation. High-resolution
immunofluorescent imaging of LUT-treated KMH2 cells, using
an anti-cleaved PARP-1 monoclonal antibody, showed a strong
nuclear focal staining pattern of cleaved PARP-1 expression,
which was absent in the DMSO-treated control cells (Figure
3B). Visible green fluorescent puncta in Figure 3B may reflect
regions where cleaved PARP-1 interacted with damaged DNA.
These results suggest that LUT-induced cell death in KMH2
proceeded through caspase-activated apoptosis. 
Discussion
LUT, a flavonoid found in common foods, has been widely
studied for its anti-cancer potential. LUT has been implicated
in the induction of apoptosis (6, 7), inhibition of cell growth
and cell cycle arrest (6, 7), and disruption of metastasis (8) and
cell migration (8, 9). Among hematological malignancies, there
is only a paucity of information on the anti-cancer activities of
LUT. In myeloid leukemia, LUT-induced leukemic apoptosis
is modulated by the differential expression of the oncoprotein
PTTG1 (pituitary tumor-transforming gene 1) (11). In multiple
myeloma, LUT treatment resulted in cell death by apoptosis
and autophagy (12). Presently, there is little or no information
on the effect of LUT on lymphoma. 
The current study showed that LUT suppresses the growth
of cHL, in vitro. Both cell lines, KMH2 and L428, showed
dose-dependent cell growth responses to LUT treatment
(Figure 1A and B). However, automated hemocytometry on
trypan blue-stained LUT-treated cells revealed a significantly
lower proportion of viable KMH2 cells compared with L428,
at higher doses (Figure 1C). Microscopic examination of LUT-
treated KMH2 cells revealed cells with compromised
membranes. Cell death analysis using AO/EtBr staining,
Annexin V-PI microscopy, and flow cytometry-PI supported
the LUT-induced apoptosis of KMH2 cells at higher doses
(Figure 2). A caspase3/7-specific fluorescent stain detected
significantly higher levels of caspase-positive LUT-treated
KMH2, at 40 μM (Figure 3A). Because KMH2 is caspase3-
deficient (16), it is likely that LUT causes activation of
caspase7 in this cell line. Upon induction of caspase
activation-associated apoptosis, leading to extensive and
irreparable DNA damage, PARP-1 is rapidly cleaved by
effector caspases (19, 20), presumably to limit further DNA
damage. It is presumed that the resulting C-terminal fragment
is shuttled out of the nucleus, leaving the N-terminal fragment
nuclear-bound. In addition, a previous study showed that
treatment of KMH2 cells with escalating concentrations of
camptothecin and doxorubicin triggered increased PARP-1
cleavage, as shown by western blot analysis using a polyclonal
antibody that detected both the cleaved and the un-cleaved
protein (18). Our result showed, using a specific monoclonal
antibody in high-resolution immunofluorescence microscopy,
nuclear focal staining of cleaved-PARP-1 (Figure 3B). These
observations suggest that LUT in part, suppresses viability of
KMH2 via caspase activation. 
Our results also showed disparate responses of either cell
line, KMH2 or L428 to LUT. Both cell lines showed similar
growth-restricting responses to LUT (Figure 1A and B), but
KMH2 cells displayed lower viability compared to L428 at
higher doses of the compound (Figure 1C). Subsequent
analyses revealed the induction of apoptosis in KMH2 cells,
which was not evident in L428 cells. Similar disparate
responses of these two cell lines to the same compound have
been observed in other studies. Celastrol inhibits
proliferation, induces apoptosis and growth arrest of KMH2
via caspase3/7 activation, whereas L428 cells were
recalcitrant to this compound (21). The difference in cellular
responses of either KMH2 or L428 to the same drug may be
related to different subtypes of cHL. KMH2 is a cellular
model of MC-cHL, and L428 of nodular sclerosis cHL.
However, it is not clear if these cHL subtypes exhibit
differential responses to chemotherapeutic drugs, in vivo.
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